Senate resolution seeks probe of glutathione drips

Senate resolution seeks probe of glutathione drips

05:12 AM March 08, 2024

Senate resolution seeks probe of glutathione drips

Sen. Nancy Binay (Voltaire Domingo and Joseph Vidal / Senate Social Media Unit)

Citing the need for “stronger regulatory oversight to prevent such tragic outcomes,” Sen. Nancy Binay has filed Senate Resolution No. 952 which seeks an investigation into the reported deaths linked to the unauthorized use of intravenous (IV) glutathione.

“It is alarming that despite warnings given by the Food and Drug Administration and the Department of Health that the use of injectable glutathione for beauty enhancement and skin treatment is unsafe and illegal, celebrities and public figures continue to endorse the same,” Binay said.

Article continues after this advertisement

READ: Binay: Mariel Padilla’s IV drip involves Senate’s integrity, safety concerns

FEATURED STORIES

She filed the measure more than a week after the controversial IV drip session of actress television host Mariel Rodriguez-Padilla inside the Senate office of her husband, Sen. Robinhood Padilla.

The couple drew a lot of flak, prompting both to apologize.

Article continues after this advertisement

Mariel also said that she received Vitamin C, not glutathione. Binay said it was the Senate’s duty to look into the unauthorized use of IV glutathione to ensure the safety of the public “by policy or by law.” —TINA G. SANTOS

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: Gluta drip, glutathione, Nancy Binay

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.